Published in Eur J Endocrinol on August 01, 2001
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging (2010) 1.69
The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int (2005) 1.05
Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab (2007) 0.87
The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab (2007) 0.83
TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause (2010) 0.83
Transient overexpression of sonic hedgehog alters the architecture and mechanical properties of trabecular bone. J Bone Miner Res (2009) 0.82
Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. J Mol Histol (2007) 0.78
Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. Climacteric (2011) 0.77
Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet (2001) 3.62
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int (1998) 2.45
Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol (2000) 2.42
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest (1994) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Uptake and transport of herpes simplex virus in neurites of rat dorsal root ganglia cells in culture. J Gen Virol (1984) 2.22
Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med (1993) 2.20
Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care (1997) 2.18
Role of NFkappaB in the mortality of sepsis. J Clin Invest (1997) 2.18
Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet (2000) 1.98
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res (1998) 1.77
Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta (2000) 1.77
Circaannual rhythms and interactions of vitamin D metabolites, parathyroid hormone, and biochemical markers of skeletal homeostasis: a prospective study. J Bone Miner Res (2000) 1.66
Counterregulation of interleukin-18 mRNA and protein expression during cutaneous wound repair in mice. J Invest Dermatol (1999) 1.58
Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes (1997) 1.48
Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest (2000) 1.45
Anthroposophic therapies in chronic disease: the Anthroposophic Medicine Outcomes Study (AMOS). Eur J Med Res (2004) 1.45
Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem (1996) 1.45
Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes (1997) 1.42
Effects of transforming growth factor-beta on osteoblastic osteosarcoma cells. Endocrinology (1987) 1.42
Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab (2001) 1.42
DNA uptake during genetic transformation and the growing zone of the cell envelope. Proc Natl Acad Sci U S A (1971) 1.41
Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes (1998) 1.40
[Thoracic pain in a power athlete]. Internist (Berl) (1997) 1.39
[The prevention of osteoporosis]. Dtsch Med Wochenschr (2001) 1.39
Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia (1999) 1.38
Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation (1997) 1.38
[Androgens and bone metabolism. Significance in osteoporosis in man and woman]. Dtsch Med Wochenschr (1992) 1.38
Binding of the competence factor to receptors in the spheroplast membrane of pneumococci. Biochem Biophys Res Commun (1970) 1.37
Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proc Natl Acad Sci U S A (1996) 1.34
Two distinct signaling pathways trigger the expression of inducible nitric oxide synthase in rat renal mesangial cells. Proc Natl Acad Sci U S A (1994) 1.33
The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors (1999) 1.33
Tumor necrosis factor increases serum leptin levels in humans. J Clin Endocrinol Metab (1997) 1.32
Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/ p44 and PI3 kinase pathways. FASEB J (2004) 1.31
A study of complaints and their relation to vertebral destruction in patients with osteoporosis. Bone Miner (1990) 1.30
The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol (1999) 1.29
Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract (2001) 1.28
Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J Clin Invest (1995) 1.27
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A (1986) 1.25
Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) (1996) 1.23
On the phylogenetic position of the pre-Neandertal specimen from Reilingen, Germany. J Hum Evol (1998) 1.21
Diabetes mellitus a risk for osteoporosis? Exp Clin Endocrinol Diabetes (2001) 1.20
Transforming growth factor beta inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci U S A (1988) 1.20
Prognostic value of codon 918 (ATG-->ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer (2001) 1.20
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). Osteoporos Int (2010) 1.19
Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol (2001) 1.19
Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J Clin Endocrinol Metab (1998) 1.17
Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology (1996) 1.17
Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J (1999) 1.16
Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes. Diabetes (1989) 1.16
Quality of life and vertebral osteoporosis. Osteoporos Int (1992) 1.15
Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med (2001) 1.15
Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care (1998) 1.15
Molecular mechanisms of inducible nitric oxide synthase gene expression by IL-1beta and cAMP in rat mesangial cells. J Immunol (1998) 1.14
Pertussis toxin abolishes angiotensin II-induced phosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells. Biochem J (1986) 1.14
Clinical grading of spinal osteoporosis: quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J Bone Miner Res (1997) 1.13
Role of phospholipase C and protein kinase C in vasoconstrictor-induced prostaglandin synthesis in cultured rat renal mesangial cells. Biochem J (1986) 1.13
Chemotactic response of osteoblastlike cells to transforming growth factor beta. J Bone Miner Res (1990) 1.13
Activation of phospholipase C and prostaglandin synthesis by [arginine]vasopressin in cultures. Biochem J (1984) 1.12
Stimulation of bone matrix apposition in vitro by local growth factors: a comparison between insulin-like growth factor I, platelet-derived growth factor, and transforming growth factor beta. Endocrinology (1990) 1.12
Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A (1996) 1.11
Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest (2001) 1.11
Stimulation by extracellular ATP and UTP of the mitogen-activated protein kinase cascade and proliferation of rat renal mesangial cells. Br J Pharmacol (1994) 1.10
Upregulation of group IB secreted phospholipase A(2) and its M-type receptor in rat ANTI-THY-1 glomerulonephritis. Kidney Int (2006) 1.10
Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res (1999) 1.10
Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents. Biochem Pharmacol (1997) 1.09
Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem J (1995) 1.09
Characterization of insulin autoantibodies in relatives of patients with type I diabetes. Diabetes (1993) 1.09
Anthroposophic vs. conventional therapy for chronic low back pain: a prospective comparative study. Eur J Med Res (2007) 1.09
Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol (2009) 1.08
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int (2012) 1.07
[Experiences with nifedipine in the treatment of acute hypertension in childhood]. Monatsschr Kinderheilkd (1985) 1.07
Tumour promotor 12-O-tetradecanoylphorbol 13-acetate inhibits angiotensin II-induced inositol phosphate production and cytosolic Ca2+ rise in rat renal mesangial cells. FEBS Lett (1986) 1.07
Inducible NO synthase: role in cellular signalling. J Exp Biol (1999) 1.06
Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res (1998) 1.06
Anti-inflammatory effects of sevoflurane and mild hypothermia in endotoxemic rats. Acta Anaesthesiol Scand (2007) 1.06
Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells. Biochem Biophys Res Commun (2000) 1.06
Selective inhibition of cyclooxygenase 2. Biochem Pharmacol (1994) 1.06
Ceramide binds to the CaLB domain of cytosolic phospholipase A2 and facilitates its membrane docking and arachidonic acid release. FASEB J (2000) 1.05
The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost (1997) 1.05
Role of protein kinase C in inhibition of renin release caused by vasoconstrictors. Am J Physiol (1986) 1.04
sn-1,2-Diacylglycerols and phorbol diesters stimulate thromboxane synthesis by de novo synthesis of prostaglandin H synthase in human promyelocytic leukemia cells. J Clin Invest (1987) 1.04
Selective ceramide binding to protein kinase C-alpha and -delta isoenzymes in renal mesangial cells. Biochemistry (1998) 1.02
Interleukin-1beta induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells. J Biol Chem (2001) 1.01
Nitric oxide donors induce stress signaling via ceramide formation in rat renal mesangial cells. J Biol Chem (1999) 1.01
Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab (2010) 1.00
Interleukin-1 beta- and forskolin-induced synthesis and secretion of group II phospholipase A2 and prostaglandin E2 in rat mesangial cells is prevented by transforming growth factor-beta 2. J Biol Chem (1992) 1.00
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Nitric oxide induces MIP-2 transcription in rat renal mesangial cells and in a rat model of glomerulonephritis. FASEB J (2001) 1.00
Large induction of the chemotactic cytokine RANTES during cutaneous wound repair: a regulatory role for nitric oxide in keratinocyte-derived RANTES expression. Biochem J (2000) 1.00
Effect of extracellular ATP on contraction, cytosolic calcium activity, membrane voltage and ion currents of rat mesangial cells in primary culture. Br J Pharmacol (1993) 1.00